Pharmaceuticals

Biologic & Biosimilar RA Drugs Industry Growth Insights: Revenue Forecast to 2030

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the biologic & biosimilar ra drugs market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Biologic & Biosimilar RA Drugs Market reach by 2030 starting from 2026 levels?

The biologic & biosimilar ra drugs market size has experienced robust growth in recent years. It is projected to increase from $14.57 billion in 2025 to $15.55 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. This historical growth can be attributed to the rising prevalence of rheumatoid arthritis, limited availability of treatment options, growing investment in biologics research, increasing healthcare expenditure, and the patent expiry of key biologics.

The biologic & biosimilar ra drugs market is projected to experience robust expansion in the coming years, anticipated to reach a valuation of $20.53 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. Factors driving this anticipated growth include the increasing acceptance of biosimilars, innovations in drug delivery technology, greater manufacturing output, supportive regulations for biologics, and heightened understanding of precision medicine. Key trends foreseen during this period encompass tailored biologic treatments, faster uptake of biosimilars, sophisticated drug delivery mechanisms, streamlined regulations for biologics, and efforts to reduce costs in RA therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

Which Drivers Are Influencing Long-Term Growth In The Biologic & Biosimilar RA Drugs Market?

We can anticipate that the growth of the biologic & biosimilar RA drug market will be driven by escalating healthcare expenditures. Healthcare spending represents the cumulative financial outlay by individuals, governments, and organizations for medical products and services, covering costs associated with preventing, treating, and managing health conditions. Biologic and biosimilar RA drugs play a crucial role in enhancing the management of rheumatoid arthritis, offering an effective yet cost-efficient approach to the specialized and often expensive therapies necessary within the realm of healthcare spending. For example, in November 2023, the CIHI, an Institute for Health Information health company located in Canada, projected that total health spending in Canada would reach $344 billion in 2023, translating to $8,740 per Canadian. This represents a 2.8% increase in 2023, following a modest 1.5% growth observed in 2022. Consequently, the expansion of healthcare spending is acting as a significant catalyst for the biologic & biosimilar RA drug market.

How Is The Biologic & Biosimilar RA Drugs Market Divided Into Segments?

The biologic & biosimilar ra drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Manufacturing: Outsourced, In-House

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources

2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines

3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

What Trends Are Driving The Growth Trajectory Of The Biologic & Biosimilar RA Drugs Market?

Companies operating within the biologic & biosimilar RA drugs market are concentrating on developing inventive solutions, such as dual-concentration biosimilar formulations, to address the growing demand for economical, available, and patient-friendly alternatives to costly biologics. Dual-concentration biosimilar options provide both high- and low-strength formulations that imitate branded biologics, ensuring smooth treatment continuity and enhanced patient convenience compared to traditional single-concentration biologics. For example, in July 2023, Organon, a US-based healthcare entity, and Samsung Bioepis, a South Korea-based biopharmaceutical firm, introduced HADLIMA, a biosimilar version of Humira (adalimumab), in the US. HADLIMA, offered in high and low concentrations, aims to boost access and affordability for patients with autoimmune conditions. This biosimilar is priced at an 85% discount relative to Humira, thus expanding patient access. HADLIMA comes with an autoinjector, endorsed by the Arthritis Foundation, and a patient support initiative, HADLIMA For You, which provides educational resources and co-pay assistance. It is prescribed for various ailments, including rheumatoid arthritis and Crohn’s disease. HADLIMA is provided in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL), ensuring seamless continuity of care for patients.

Which Key Market Players Are Investing In Expansion And Innovation Within The Biologic & Biosimilar RA Drugs Market?

Major companies operating in the biologic & biosimilar ra drugs market are Samsung BioLogics Co. Ltd., Amgen Inc., AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Which Regions Are Poised For Strategic Growth In The Biologic & Biosimilar RA Drugs Market?

North America was the largest region in the biologic & biosimilar RA drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biologic & Biosimilar RA Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp

Browse Through More Reports Similar to the Global Biologic & Biosimilar RA Drugs Market 2026, By The Business Research Company

Biologic And Biosimilar Ra Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Rheumatoid Arthritis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Rheumatoid Arthritis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795